1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Biogen Inc.

Biogen Inc.

BIIB
Biogen Inc.US flagNASDAQ Global Select
199.71
USD
+3.13
- -
29.48BMarket Cap
Biogen Inc.
BIIB
(NASDAQ Global Select)

Recent

price

199.71

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
18.69
20.83
23.18
29.26
41.05
46.66
52.42
57.73
65.66
76.85
83.56
73.65
70.02
67.97
66.46
67.51
67.72
Revenue per Share
3.98
5.09
5.8
7.86
12.42
15.37
16.95
11.94
21.62
31.47
24.86
10.44
20.97
8.02
11.21
8.83
9.35
Basic EPS, GAAP
5.75
6.27
6.83
-4.91
11.11
14.14
17.67
12.17
25.87
34.25
22.86
22.43
7.85
8.54
17.28
13.44
15.78
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
7.42
12.82
18.86
26.8
39.28
52.92
69.01
74.37
79.34
87.95
86.86
93.31
113.33
121.82
132.28
140.29
142.23
Book Value per Share
10.03
15.15
17.36
12.3
21.26
11.38
21.3
19.22
20.52
21.67
11.43
19.97
39.84
1.5
3.75
17.66
21.19
Tangible Book Value per Share
252
242
238
237
236
231
218
213
205
187
161
149
145
145
146
146
147
Basic Weighted Avg Shares
4,716
5,049
5,516
6,932
9,703
10,764
11,449
12,274
13,453
14,378
13,445
10,982
10,173
9,836
9,676
9,891
9,937
Sales/Revenue/Turnover
33.27
35.25
33.33
35.92
40.37
46.59
49.39
45.05
44.61
48.93
33.07
25.57
28.52
18.79
23.57
24.96
23.18
Operating Margin (%)
356
359
366
532
688
600
683
1,081
650
465
457
488
518
495
673
780
801
Depreciation Expense
1,005
1,234
1,380
1,862
2,935
3,547
3,703
2,539
4,431
5,888
4,001
1,556
3,047
1,161
1,632
1,293
1,372
Net Income, GAAP
26.94
25.98
25.37
24.23
25.08
24.37
25.08
47.94
24.16
16.25
19.66
3.01
17.62
10.43
14.37
16.94
15.47
Effective Tax Rate (%)
21.31
24.45
25.02
26.86
30.25
32.95
32.34
20.69
32.93
40.96
29.76
14.17
29.95
11.81
16.87
13.07
13.81
Profit Margin (%)
1,490
2,063
1,587
1,427
2,317
4,123
5,312
4,505
4,346
3,518
3,145
3,558
6,518
3,425
1,928
5,625
6,192
Working Capital
1,066
1,061
687
592
580
6,522
6,513
5,935
5,936
4,872
7,828
6,604
6,614
7,188
4,882
6,577
6,562
LT Debt
5,449
6,427
6,964
8,621
10,814
9,375
12,129
12,598
13,032
13,339
10,686
10,960
13,388
14,799
16,716
18,257
18,652
Total Equity
16.29
18.61
17.59
21.54
28
27.41
24.22
15.36
24.18
30.37
18.59
14.57
12.26
7.76
8.44
8.4
7.86
Return on Invested Capital (%)
42.65
33.6
28.71
30
35.08
24.98
19.37
11.72
20.67
26.87
18.47
7.52
14.94
5.75
7.26
5.72
5.99
Return on Capital (%)
68.35
49.58
36.35
34.37
37.55
33.01
27.15
16.44
27.63
36
26.29
11.16
20.06
6.81
8.85
6.49
6.8
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
6,285
6,287
6,288
LT Finance Leases
305
290
273
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
147
147
148
Market Capitalization
20,483
25,778
26,904

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
8,937
8,974
9,190
Cash, Cash Equivalents & STI
3,960
3,816
4,283
Accounts Receivable, Net
1,850
1,867
1,790
Inventories
2,209
2,168
1,949
Total Current Liabilities
3,290
3,349
2,999
Payables & Accruals
2,890
2,974
2,806
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.66%
11.49%
9.22%
Free Cash Flow
8.37%
3.04%
-21.72%
Net Income, GAAP
4.09%
-1.48%
-20.79%
Sales/Revenue/Turnover
-0.48%
-5.68%
2.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,290
2,465
2,466
2,455
9,676
2025
2,431
2,646
2,535
2,279
9,891
2026
2,478
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.71
4.01
2.67
1.83
11.21
2025
1.65
4.33
3.18
-0.33
8.83
2026
2.17
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Novo Nordisk A/S (NOVO-B.CO)
Roche Holding AG (RHHVF)
CSPC Pharmaceutical Group Limited (CHJTF)
Citius Oncology, Inc. (CTOR)
NGL Fine-Chem Limited (NGLFINE.NS)
JCR Pharmaceuticals Co., Ltd. (4552.T)
Business
Biogen Inc. (BIIB) discovers, develops, manufactures and commercializes therapies for neurological and neurodegenerative diseases, hemophilia, multiple sclerosis (MS), spinal muscular atrophy (SMA), lupus and rare diseases worldwide; core products include Tecfidera and Vumerity (dimethyl and diroximel fumarate) for MS, Avonex (interferon beta-1a), Plegridy (peginterferon beta-1a) and Tysabri (natalizumab) for relapsing MS, Spinraza for SMA, Leqembi for Alzheimer's disease, Skyclarys for Friedreich's ataxia and anti-CD20 therapies such as Rituxan and Gazyva for certain B-cell malignancies and autoimmune conditions. The company, founded in 1978 and headquartered in Cambridge, Massachusetts, operates in the United States, Europe, Asia and other international markets. Recent developments include the completion of its acquisition of Alcyone Therapeutics in November 2025 to bolster rare disease capabilities, a November 2025 collaboration with Dayra Therapeutics featuring a $50 million upfront payment for oral macrocyclic peptides targeting immunology, a February 2025 R&D funding agreement with Royalty Pharma worth up to $250 million for Phase 3 litifilimab in lupus, expansion of Leqembi with U.S. approval of the IQLIK subcutaneous formulation, an agreement to acquire Sage Therapeutics and groundbreaking in September 2025 for a new 580,000-square-foot headquarters at 75 Broadway set for completion in 2028 coinciding with the company's 50th anniversary.

Company News

APIChatGPT

  • feeds.benzinga.com

    Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline

  • zacks.com

    Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

  • reuters.com

    Biogen to acquire RayThera for $1 billion

  • globenewswire.com

    Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

  • forbes.com

    The Healthcare M&A Wave

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

  • prnewswire.com

    BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

  • benzinga.com

    Congresswoman Who Bought No Stocks In 2025 Is Back With More 2026 Trades: Here's The Shopping List

  • globenewswire.com

    BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

  • benzinga.com

    This Biogen Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday

  • prnewswire.com

    BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

  • zacks.com

    BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag

  • gurufocus.com

    BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

  • businesswire.com

    BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

  • globenewswire.com

    Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

  • globenewswire.com

    EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus